SCHEMBL25255812

SCHEMBL25255812

Cc1ccc(CCn2nc(C)c3cc(O)c4ccccc4c32)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GFER P55789 1/20 0.38
▸ GLS O94925 1/20 0.37
▸ GRN P28799 1/20 0.36
▸ SORT1 Q99523 1/20 0.36
▸ IGF1R P08069 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ CASP3 P42574 1/20 0.35
▸ CASP7 P55210 1/20 0.35
▸ SRC P12931 1/20 0.35
▸ PRKACA P17612 1/20 0.35
▸ PRKACG P22612 1/20 0.35
▸ PRKACB P22694 1/20 0.35
▸ PDE10A Q9Y233 1/20 0.35
▸ GAA P10253 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34
▸ HDAC3 O15379 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29404923 1.00 GFER (0.38) GFERGLSGRNSORT1IGF1R
SCHEMBL25300658 0.92 MAPK1 (0.42) GFERGLSGRNSORT1MAPK1
SCHEMBL29404961 0.92 MAPK1 (0.42) GFERGLSGRNSORT1MAPK1
SCHEMBL25301767 0.90 KMT2A (0.41) GFERGLS
SCHEMBL29402010 0.86 SRC (0.46) GLSIGF1RALOX15MAPK1SRC
SCHEMBL25296141 0.86 SRC (0.46) GLSIGF1RALOX15MAPK1SRC
SCHEMBL29402377 0.82 ALDH1A1 (0.40) GLSPDE10AGAAALDH1A1POLB
SCHEMBL25302428 0.82 ALDH1A1 (0.40) GLSPDE10AGAAALDH1A1POLB
SCHEMBL25263468 0.80 GRN (0.36) GFERGRNSORT1IGF1RALOX15
SCHEMBL30253404 0.80 GRN (0.36) GFERGRNSORT1IGF1RALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same LMITO THERAPEUTICS INC. (KR) 2026-03-10 — — US disclosed
US-20240034719-A1 IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME LMITO THERAPEUTICS INC. (KR) 2024-02-01 — — US disclosed
EP-4212530-A1 IMIDAZOLQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME Lmito Therapeutics Inc. (KR) 2023-07-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034719-A1 IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME NQO1, NFE2L2, KEAP1 GFER 1293/4885GLS 512/4885GRN 3653/4885
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same NQO1, CBR1, NFE2L2 GFER 1221/4885GLS 415/4885GRN 3960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback